Literature DB >> 10187395

Protection of human subjects: categories of research that may be reviewed by the Institutional Review Board (IRB) through an expedited review procedure--FDA. Notice.

.   

Abstract

On November 10, 1997, the Food and Drug Administration (FDA), in consultation with the Office for Protection from Research Risks (OPRR) at the National Institutes of Health, requested written comments relating to the proposed republication of the list that identifies certain research activities involving human subjects that may be reviewed by the Institutional Review Board (IRB) through the expedited review procedure authorized in 21 CFR 56.110. The comment period closed on March 10, 1998. FDA and OPRR received a combined total of 108 comments. After a review of the comments, FDA and OPRR are now simultaneously publishing identical revised lists of categories of research activities that may be reviewed by the IRB through the expedited review procedure.

Entities:  

Mesh:

Year:  1998        PMID: 10187395

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  15 in total

1.  Streamlining ethical review.

Authors:  Joseph Millum; Jerry Menikoff
Journal:  Ann Intern Med       Date:  2010-11-16       Impact factor: 25.391

Review 2.  A decision tool to guide the ethics review of a challenging breed of emerging genomic projects.

Authors:  Yann Joly; Derek So; Gladys Osien; Laura Crimi; Martin Bobrow; Don Chalmers; Susan E Wallace; Nikolajs Zeps; Bartha Knoppers
Journal:  Eur J Hum Genet       Date:  2016-01-20       Impact factor: 4.246

Review 3.  Conducting a successful residency research project.

Authors:  Jeffrey F Barletta
Journal:  Am J Pharm Educ       Date:  2008-08-15       Impact factor: 2.047

4.  Establishing Consumer Protections for Research in Human Service Agencies.

Authors:  Linda A LeBlanc; Melissa R Nosik; Anna Petursdottir
Journal:  Behav Anal Pract       Date:  2018-04-12

Review 5.  Human subjects issues and IRB review in practice-based research.

Authors:  Leslie E Wolf; Janice Ferrara Walden; Bernard Lo
Journal:  Ann Fam Med       Date:  2005 May-Jun       Impact factor: 5.166

6.  Setting risk thresholds in biomedical research: lessons from the debate about minimal risk.

Authors:  Annette Rid
Journal:  Monash Bioeth Rev       Date:  2014 Mar-Jun

7.  Minimal risk in research involving pregnant women and fetuses.

Authors:  Carson Strong
Journal:  J Law Med Ethics       Date:  2011       Impact factor: 1.718

Review 8.  Ethics of drug studies in the newborn.

Authors:  Robert M Ward; Catherine M T Sherwin
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

9.  Confronting and resolving an ethical dilemma associated with a practice based evaluation using observational methodology of health information technology.

Authors:  P S Sockolow; H A Taylor
Journal:  Appl Clin Inform       Date:  2010-07-28       Impact factor: 2.342

Review 10.  The law of incidental findings in human subjects research: establishing researchers' duties.

Authors:  Susan M Wolf; Jordan Paradise; Charlisse Caga-anan
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.